Education
About Us
Working with TipRanks
Follow Us
RxSight (RXST)
NASDAQ:RXST
RXST Stock Chart & Stats
Day’s Range― - ―
52-Week Range$12.53 - $60.81
Previous CloseN/A
Volume110.15K
Average Volume (3M)1.09M
Market Cap
$642.47M
Enterprise Value$526.31M
Total Cash (Recent Filing)$237.22M
Total Debt (Recent Filing)$12.30M
Price to Earnings (P/E)―
Beta1.49
Next Earnings
Aug 11, 2025EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.20
Shares Outstanding40,636,982
10 Day Avg. Volume743,625
30 Day Avg. Volume1,089,260
Financial Highlights & Ratios
PEG Ratio-1.45
Price to Book (P/B)1.87
Price to Sales (P/S)0.00
P/FCF Ratio-23.62
Enterprise Value/Market Cap0.82
Enterprise Value/Revenue1.01
Enterprise Value/Gross Profit5.32
Enterprise Value/Ebitda-4.36
Forecast
1Y Price Target
$22.56Price Target Upside51.21% Upside
Rating ConsensusHold
Number of Analyst Covering9
RxSight News
See All RXST News
Bulls Say, Bears Say
Bulls Say
International ExpansionInternational markets represent a significant opportunity for RXST, with plans to enter European and Asian markets where the advanced technology IOL market is twice the size of the US market.
Market PositionRXST has a strong first-mover advantage in the light adjustable lenses market, having captured about 10% of the advanced technology intraocular lens market since its launch.
ValuationRXST's valuation appears very attractive, trading at a significant discount to its peers, with above-average growth, a strong moat, and high gross margins.
Bears Say
CompetitionCompetition and consumer confidence are risks as other companies are launching competing AT-IOLs in the US, potentially impacting RXST’s growth.
Revenue PerformanceRXST reported 1Q25 revenue of $37.9M, which was below initial consensus estimates by around 4.7%.
UtilizationOverall utilization per system per month decreased by 6% year-over-year.
Ownership Overview
4.85% Insiders
19.00% Mutual Funds
36.02% Other Institutional Investors
23.46% Public Companies and Individual Investors
RXST FAQ
What was RxSight’s price range in the past 12 months?
RxSight lowest stock price was $12.53 and its highest was $60.81 in the past 12 months.
What is RxSight’s market cap?
RxSight’s market cap is $642.47M.
When is RxSight’s upcoming earnings report date?
RxSight’s upcoming earnings report date is Aug 11, 2025 which is in 65 days.
How were RxSight’s earnings last quarter?
RxSight released its earnings results on May 07, 2025. The company reported -$0.2 earnings per share for the quarter, beating the consensus estimate of -$0.217 by $0.017.
Is RxSight overvalued?
According to Wall Street analysts RxSight’s price is currently Undervalued.
Does RxSight pay dividends?
RxSight does not currently pay dividends.
What is RxSight’s EPS estimate?
RxSight’s EPS estimate is -0.17.
How many shares outstanding does RxSight have?
RxSight has 40,636,982 shares outstanding.
What happened to RxSight’s price movement after its last earnings report?
RxSight reported an EPS of -$0.2 in its last earnings report, beating expectations of -$0.217. Following the earnings report the stock price went down -11.208%.
Which hedge fund is a major shareholder of RxSight?
Currently, no hedge funds are holding shares in RXST
RxSight Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$22.56 (51.21% Upside)
$22.56 (51.21% Upside)
Blogger Sentiment
Bullish
RXST Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 447.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $100.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 31.7%
Last 30 Days ▲ 27.6%
Last 30 Days ▲ 27.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-73.24%
12-Months-Change
Fundamentals
Return on Equity
-11.98%
Trailing 12-Months
Asset Growth
70.91%
Trailing 12-Months
Company Description
RxSight
RxSight, Inc. (RXST) operates in the healthcare sector, focusing on ophthalmic innovations. The company is known for its development and commercialization of the Light Adjustable Lens (LAL), a breakthrough in cataract surgery that allows for postoperative vision adjustments to improve patient outcomes. RxSight is committed to enhancing vision care through advanced technology and improving the quality of life for patients undergoing cataract surgeries.
RXST Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call revealed strong revenue growth and customer satisfaction but was overshadowed by the revision of revenue guidance due to macroeconomic challenges and market competition. While European regulatory approval presents a long-term opportunity, short-term challenges persist, affecting performance and outlook.Read More>RXST Stock 12 Month Forecast
Average Price Target
$22.56
▲(51.21%Upside)